what this node claims
AlphaFold metrics / TGFB1
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
80%structureusable
pLDDT 79.59
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 79.59
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 79.59
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
390 residues / min 36.41 / max 97.88 / source alphafold db
Very high
40.3%
157 residues / >=90
Confident
32.3%
126 residues / 70-89
Low
20.8%
81 residues / 50-69
Very low
6.7%
26 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 390 of 390 residues.
- residues 1-36 / mean 47.64
- residues 269-291 / mean 54.88
- residues 92-104 / mean 57.73
- residues 240-252 / mean 60.56
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.